Biopharma Companies – But Not PhRMA – Argue That Mifepristone Ruling ‘Radically Alters’ NDA Process

BIO signs on while PhRMA and AAM stay on the sidelines as 169 companies, executives and investors file amicus brief supporting FDA’s request for stay of Judge Kacsmaryk’s decision to halt approval of the medication abortion drug. Members of Congress file opposing briefs.